NCT05335473 2023-04-06Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureHenan Cancer HospitalPhase 1/2 Unknown87 enrolled
NCT02864030 2021-03-04PAINTER: Polymorphism And INcidence of Toxicity in ERibulin TreatmentOncologia Medica dell'Ospedale FatebenefratelliPhase 4 Completed200 enrolled